To the Editor,

 {#all14090-sec-0001}

Anaphylaxis is a life‐threatening clinical emergency, and prompt intramuscular (IM) injection of epinephrine is critical.[1](#all14090-bib-0001){ref-type="ref"}, [2](#all14090-bib-0002){ref-type="ref"}, [3](#all14090-bib-0003){ref-type="ref"} Current practices pertaining to the initial treatment of anaphylaxis in China remain unclear. In this study, we assessed the actual initial treatment and the use of epinephrine for anaphylaxis in China by systematic analysis of published case reports between 2014 and 2018.

 {#all14090-sec-0002}

An online literature search was performed in PubMed, Web of Science, ScienceDirect, China National Knowledge Internet database (<http://www.cnki.net>), Wanfang database (<http://med.wanfangdata.com.cn>), and VIP database (<http://www.cqvip.com>). The following key words were used: "anaphylaxis," "anaphylactic reactions," "anaphylactic reaction," "anaphylactic shock," "reactions, anaphylactic," "reaction, anaphylactic," "shock, anaphylactic," "kounis," "kounis syndrome," and "china". The inclusion criteria were as follows: (a) diagnosis of anaphylaxis[1](#all14090-bib-0001){ref-type="ref"}; (b) availability of records about the anaphylaxis; (c) published from January 1, 2014, to December 31, 2018; (d) published in English or Chinese. Exclusion criteria were as follows: (a) cases with incomplete data; (b) duplicate publication; (c) cases in which cardiac arrest occurred prior to the administration of epinephrine. Overdose of epinephrine was defined as administration of a dose that exceeded the dose recommended by the guidelines. [2](#all14090-bib-0002){ref-type="ref"}, [3](#all14090-bib-0003){ref-type="ref"}, [4](#all14090-bib-0004){ref-type="ref"}

 {#all14090-sec-0003}

A total of 7579 articles were retrieved on database search, and a total of 819 patients from 748 case reports were included in this review (Figure [S1](#all14090-sup-0001){ref-type="supplementary-material"}). These patients were distributed across 30/31 (96.8%) provinces in mainland China except Tibet (Figure [S2](#all14090-sup-0002){ref-type="supplementary-material"}). Patient characteristics are summarized in Table [S1](#all14090-sup-0003){ref-type="supplementary-material"}. The median age was 46.1 years, and 53.0% patients were male. More than 2/3rd of the episodes of anaphylaxis occurred among inpatients. All the patients except one (99.9%) presented severe anaphylactic reactions (cardiovascular and/or respiratory compromise). The mortality rate was 5.6%.

 {#all14090-sec-0004}

Removal of the likely trigger (57.3%) and supplemental oxygen (42.1%) were the 2 most commonly administered initial treatment followed by glucocorticoids (19.8%) and intravenous (IV) fluid support (14.9%; Table [1](#all14090-tbl-0001){ref-type="table"}). Only 14.2% patients were appropriately treated with epinephrine as the first‐line intervention. The percentage of patients treated with glucocorticoids was significantly higher than the percentage of those treated with epinephrine as the first‐line treatment (19.8% vs. 14.2%; *P* \< .001), as the first‐line medication (44.3% vs. 38.5%, *P* = .016), or during the course of anaphylaxis (94.7% vs. 70.8%, *P* \< .001).

###### 

Treatment of patients with anaphylaxis

                                                      Patients with available data, n   Value
  --------------------------------------------------- --------------------------------- ------------------------------------------------------
  First‐line treatment, n (%)                                                           
  Removal of the trigger                              819                               469 (57.3)
  Oxygen                                              819                               345 (42.1)
  Glucocorticoid                                      819                               162(19.8)[\*](#all14090-note-0002){ref-type="fn"}
  Fluid                                               819                               122 (14.9)
  Epinephrine                                         819                               116 (14.2)
  Vasopressor                                         819                               34 (4.2)
  H1‐antihistamine                                    819                               25 (3.1)
  Atropine                                            819                               5 (0.6)
  Calcium gluconate                                   819                               4 (0.5)
  Aminophylline                                       819                               2 (0.2)
  TCM                                                 819                               2 (0.2)
  Beta‐2‐agonist                                      819                               1 (0.1)
  NSAIDs                                              819                               1 (0.1)
  First‐line medication, n (%)                                                          
  Glucocorticoid                                      819                               363 (44.3)[\*\*](#all14090-note-0003){ref-type="fn"}
  Epinephrine                                         819                               315 (38.5)
  Vasopressor                                         819                               62 (7.6)
  H1‐antihistamine                                    819                               51 (6.2)
  Calcium gluconate                                   819                               7 (0.9)
  Atropine                                            819                               5 (0.6)
  Aminophylline                                       819                               4 (0.5)
  Respiratory stimulant                               819                               4 (0.5)
  TCM                                                 819                               3 (0.4)
  Beta‐2‐agonist                                      819                               2 (0.2)
  NSAIDs                                              819                               1 (0.1)
  Fluid                                               819                               1 (0.1)
  No medication                                       819                               1 (0.1)
  Treatment during the course of anaphylaxis, n (%)                                     
  Epinephrine                                         819                               580 (70.8)
  Oxygen                                              819                               648 (79.1)
  Nasal catheter                                      648                               484 (74.7)
  Face mask                                           648                               82 (12.7)
  Endotracheal intubation                             648                               77 (11.9)
  Noninvasive ventilator                              648                               3 (0.5)
  Tracheotomy                                         648                               2 (0.3)
  Fluid support                                       819                               583 (71.2)
  Normal saline                                       583                               229 (39.3)
  Glucose solution                                    583                               83 (14.2)
  Balanced solution                                   583                               71 (12.2)
  Colloid solution                                    583                               64 (11.0)
  Glucose saline                                      583                               17 (2.9)
  TCM solution                                        583                               1 (0.2)
  50% Glucose solution                                583                               1 (0.2)
  Unspecified                                         583                               117 (20.1)
  Inhaled beta‐2 agonists                             819                               10 (1.2)
  H1‐antihistamines                                   819                               343 (41.9)
  H2‐antihistamines                                   819                               12 (1.5)
  Glucocorticoids                                     819                               776 (94.7)[\*](#all14090-note-0002){ref-type="fn"}
  Dexamethasone                                       776                               683 (88.0)
  Methylprednisolone                                  776                               72 (9.3)
  Hydrocortisone                                      776                               20 (2.6)
  Unspecified                                         776                               1 (0.1)
  Vasopressors                                        819                               382 (46.6)

Data presented as frequency (%) unless indicated otherwise. Removal of the trigger (57.3%), oxygen (42.1%), glucocorticoid (19.8%), and IV fluid support (14.9%) were the top 4 most commonly administered first‐line interventions. Only 14.2% patients were treated with epinephrine as the initial treatment. In the analysis of first‐line medications, 315 patients (38.5%) were administered epinephrine; glucocorticoids (44.3%) were the most commonly used drugs. Compared to the percentage of patients treated with epinephrine that of patients treated with corticosteroids were significantly higher as the first‐line treatment (*χ* ^2^ = 298.029, *P* \< .001), as the first‐line medication (*χ* ^2^ = 5.798, *P* = .016), or during the course of anaphylaxis (*χ* ^2^ = 164.557, *P* \< .001), respectively. TCM, traditional Chinese medicine and NSAIDs, nonsteroid anti‐inflammatory drugs.

*P* \< .01.

*P* \< .05 vs percentage of patients treated with epinephrine.

John Wiley & Sons, Ltd

 {#all14090-sec-0005}

Out of the 580 patients who received epinephrine (Table [2](#all14090-tbl-0002){ref-type="table"}), the initial dosage of epinephrine showed wide variability from 0.03 to 3 mg in children and form 0.01 to 20 mg in adults.[5](#all14090-bib-0005){ref-type="ref"}, [6](#all14090-bib-0006){ref-type="ref"}, [7](#all14090-bib-0007){ref-type="ref"}, [8](#all14090-bib-0008){ref-type="ref"}

###### 

Initial dosage and route of administration of epinephrine

<table><thead><tr class="header"><th>Administration of epinephrine in patients with available data</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr class="odd"><td><p>Children</p><p>(54)</p></td><td>&gt;0.5</td><td>1</td><td>2</td><td>4</td><td>0</td><td>0</td><td>0</td><td>7</td><td>7</td></tr><tr class="even"><td>0.5</td><td>2</td><td>7</td><td>4</td><td>0</td><td>0</td><td>0</td><td>13</td><td>13</td><td></td></tr><tr class="odd"><td>0.4</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td><td></td></tr><tr class="even"><td>0.3</td><td>4</td><td>5</td><td>5</td><td>0</td><td>0</td><td>0</td><td>14</td><td>12</td><td></td></tr><tr class="odd"><td>&lt;0.3</td><td>0</td><td>5</td><td>6</td><td>1</td><td>0</td><td>2</td><td>14</td><td>9</td><td></td></tr><tr class="even"><td>Unspecified</td><td>0</td><td>2</td><td>2</td><td>0</td><td>0</td><td>1</td><td>5</td><td>NA</td><td></td></tr><tr class="odd"><td>Total</td><td>7</td><td>21</td><td>21</td><td>2</td><td>0</td><td>3</td><td>54</td><td>42</td><td></td></tr><tr class="even"><td><p>Adults</p><p>(526)</p></td><td>&gt;1.0</td><td>1</td><td>1</td><td>13</td><td>0</td><td>0</td><td>1</td><td>16</td><td>16</td></tr><tr class="odd"><td>1.0</td><td>50</td><td>115</td><td>135</td><td>1</td><td>1</td><td>0</td><td>302<a href="#all14090-note-0005" data-ref-type="fn">a</a></td><td>302</td><td></td></tr><tr class="even"><td>0.7</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td><td></td></tr><tr class="odd"><td>0.5</td><td>24</td><td>52</td><td>37</td><td>0</td><td>0</td><td>3</td><td>116</td><td>37</td><td></td></tr><tr class="even"><td>&lt;0.5</td><td>6</td><td>9</td><td>27</td><td>3</td><td>0</td><td>3</td><td>48</td><td>29</td><td></td></tr><tr class="odd"><td>Unspecified</td><td>0</td><td>2</td><td>15</td><td>3</td><td>0</td><td>23</td><td>43</td><td>NA</td><td></td></tr><tr class="even"><td>Total</td><td>81</td><td>179</td><td>228<a href="#all14090-note-0006" data-ref-type="fn">b</a>, <a href="#all14090-note-0007" data-ref-type="fn">c</a></td><td>7</td><td>1</td><td>30</td><td>526</td><td>385</td><td></td></tr><tr class="odd"><td>Total</td><td> </td><td>88</td><td>200</td><td>249</td><td>9</td><td>1</td><td>33</td><td>580</td><td>427</td></tr></tbody></table>

Data presented as frequency (n) unless indicated otherwise. In children, the top 2 common doses of epinephrine were 0.3 mg (28.6%) and 0.5 mg (26.5%), and the top 2 common routes of epinephrine were IV bolus injection and SC injection (both 41.2%). In children, the percentage of epinephrine overdose by IM injection, SC injection, IV bolus injection, and IV infusion was 71.4%, 73.7%, 100.0%, and 100%, respectively. In adults, the percentage of patients who received a dose of 1.0 mg (62.5%) was significantly higher than that of 0.5 mg (24.0%; *χ* ^2^ = 129.391, *P* \< .001).The number of patients who received IM, SC, IV bolus injection and IV infusion was 81 (16.3%), 179 (36.1%), 228 (46.0%), and 7 (1.4%), respectively. Among the 476 patients with record of both the epinephrine dose and the route, 385 (80.9%) patients received an overdose of epinephrine. The percentage of overdose was significantly more likely with IV bolus injection (99.5%) as compared to that with IM injection (63.0%; *χ* ^2^ = 89.064, *P* \< .001) or SC injection (65.5%; *χ* ^2^ = 85.639, *P* \< .001). IM, Intramuscular; SC, Subcutaneous; IV, intravenous; NA, not available.

*P* \< .01 vs 0.5 mg.

*P* \< .01 vs IM injection.

*P* \< .01 vs SC injection.

John Wiley & Sons, Ltd

Among children, the two most commonly administered initial doses of epinephrine were 0.3 mg (28.6%) and 0.5 mg (26.5%), and the two most common routes of administration were IV bolus injection (41.2%) and subcutaneous (SC) injection (41.2%). Only seven children (13.7%) received epinephrine by IM route. Most (89.4%) of children were administered an initial overdose of epinephrine. The percentage of children who received epinephrine overdose by IV bolus injection, SC injection, and IM injection was 100.0%, 73.7%, and 71.4%, respectively.

Among adult patients, the percentage of patients who received an initial dose of 1.0 mg (62.5%) was significantly higher than the percentage of those who received 0.5 mg (24.0%; *P* \< .001). The percentage of patients who received epinephrine via IM injection (16.3%) was significantly lower than those who received IV bolus (46.0%, *P* \< .001) or SC injection (36.1%, *P* \< .001). Out of the 476 patients for whom the records of the epinephrine dose and the route of administration were available, 385 (80.9%) patients received an initial overdose of epinephrine. The percentage of overdose was more common with IV bolus injection (99.5%) as compared to IM injection (63.0%; *P* \< .001) or SC injection (65.5%; *P* \< .001).

 {#all14090-sec-0006}

Out of 580 patients who received epinephrine, 54 (9.3%) developed serious adverse effects associated with epinephrine (Table [S2](#all14090-sup-0004){ref-type="supplementary-material"}), including ventricular arrhythmias (59.3%), hypertension (20.4%), pulmonary edema (13.0%), myocardial ischemia (5.6%), and stroke (1.9%). Among the 52 patients with complete records of both the dose and route of administration of epinephrine, 50 (96.2%) patients had received an overdose and 45 (86.5%) were administered epinephrine by IV bolus injection.

 {#all14090-sec-0007}

To the best of our knowledge, this is the first study that evaluated the actual initial treatment of anaphylaxis in China based on a literature review. Due to the space limitation, only four of the 748 studies included in this review were referenced. Our results indicated considerable underuse of epinephrine as the initial treatment of anaphylaxis. In contrast, glucocorticoids were inappropriately used as the first‐line drug in place of epinephrine. Moreover, 81.6% patients had received an overdose of epinephrine, and 45.5% patients received IV bolus injection, both of which were proved to be significantly associated with serious adverse effects of epinephrine. Our findings suggest that the actual initial treatment of anaphylaxis in China does not comply with the international anaphylaxis guidelines. Of note, none of these problems was discussed or mentioned in these reports. This implies a general lack of awareness about the gaps in the initial treatment of anaphylaxis among many Chinese healthcare professionals.[9](#all14090-bib-0009){ref-type="ref"} Our findings call for concerted efforts to remedify the current situation and to promote the safety of Chinese patients with anaphylaxis.

 {#all14090-sec-0008}

The study has a selection bias because the cases come from published reports. However, a large enough sample size helped negate this limitation to a certain extent. We established rigorous inclusion/exclusion criteria to minimize the risk of bias, and a thorough literature search was performed to include more cases of anaphylaxis. Moreover, Inclusion of Chinese literature helped increase the yield of cases and improved the representativeness of our findings.

 {#all14090-sec-0009}

Our study highlights some critical gaps in the initial treatment of anaphylaxis in China when compared against the international guidelines. Underuse, overdose, and inappropriate route of administration of epinephrine, as well as overuse of glucocorticoids, are the major problems. The epinephrine overdose and administration of IV bolus injection significantly increase the risk of serious adverse effects of epinephrine. Targeted training on the initial treatment of anaphylaxis is strongly suggested for healthcare providers in China.
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